Meningococcal Serogroup B (MenB) Vaccine
This 22-year-old patient with sickle cell disease needs a meningococcal serogroup B (MenB) vaccine series. While the patient has received meningococcal conjugate vaccine (MCVP, which covers serogroups A, C, W, and Y), there is no documentation of MenB vaccination, which is specifically recommended for patients with sickle cell disease due to their functional asplenia.
Why MenB Vaccine is Critical
Patients with sickle cell disease have functional asplenia, placing them at significantly increased risk for invasive meningococcal disease from all serogroups, including serogroup B. The 2020 ACIP guidelines explicitly categorize sickle cell disease under "anatomic and functional asplenia" and provide clear vaccination schedules 1.
Specific Vaccination Recommendation
For patients ≥10 years of age with sickle cell disease 1:
Primary vaccination series:
- MenB-FHbp (Trumenba): 3 doses at 0,1-2, and 6 months, OR
- MenB-4C (Bexsero): 2 doses ≥1 month apart
Important: These two MenB vaccines are not interchangeable—use the same product for all doses in the series 1.
Booster doses (if the patient remains at increased risk, which applies to sickle cell disease):
- Single booster dose at 1 year after completion of primary vaccination
- Then every 2-3 years thereafter 1
Additional Considerations
MenACWY Booster Status
The patient received MCVP (meningococcal conjugate vaccine covering A, C, W, Y) on two occasions. For patients with sickle cell disease aged ≥10 years who received a 2-dose primary series, booster doses are recommended every 5 years if they remain at increased risk 1. Depending on when the last MCVP dose was given, a booster may also be due.
Pneumococcal Vaccination
The patient received PCV20, which is appropriate. No additional pneumococcal vaccination is needed at this time, as PCV20 provides comprehensive coverage 2.
Common Pitfall
Do not assume that meningococcal conjugate vaccine (MenACWY) provides protection against serogroup B—it does not. Serogroup B requires a separate vaccine series 3. This is a critical gap that leaves patients with sickle cell disease vulnerable to invasive meningococcal disease from serogroup B, which accounts for a significant proportion of meningococcal cases in adolescents and young adults.
Timing Consideration
MenB vaccines can be administered concomitantly with other vaccines at different anatomic sites 1. There is no need to delay vaccination.